TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Bleeding/Spotting Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in A1C (glycated hemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recommended Phase 2 Dose by Identification of Any Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes from baseline Arthritis Helplessness Index (AHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with Treatment related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: behavioral responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Transepithelial electrical resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Exhibit Positive Responses to Each Allergen Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline of isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of DNA/RNA damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of protein carbonyls levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ≥50% intracranial aneurysm size reduction success at 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Aneurysm occlusion success at 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Odalasvir (ODV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability for ODV
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability for AL-335
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of HostDx Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prognostic accuracy of HostDx Sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of epipericardial fat necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Solicited Administration site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Best objective tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Tumor Cell Proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Log MAR visual acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total skills score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of life as measured by the EQ-5D health index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life as measured by the SF-36 sub scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Human Skin Hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Human Skin Sebum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Human Skin Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of responder subjects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vasoconstriction response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes From Baseline in Young Mania Rating Scale (YMRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxygen consumption at anaerobic threshold (VO2AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Brief Pain Inventory (BPI) Pain Severity and Interference Score From Baseline Through 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Worst Stiffness Score From Baseline Through 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PROMIS Physical Function Score From Baseline Through 24 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Fibrinogen at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Interleukin 6 (IL-6) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in viral cultures and titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Performance/Ease of Use
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ease of Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residue Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual deformity after reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of quality of life - total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sUA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Common carotid artery intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Rescue Analgesics Requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of discontinuation of Epi-PCA
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of crow's feet lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change in Target Area Total Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in prevalence of dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrence of events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the number of cells in the A/C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Safety and Effectiveness Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of fatty liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in chronic inflammatory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of the technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular parameters obtained on echocardiogram (longitudinal strain and E/E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angiogenic factors and biomarkers of congestive heart failure (sFlt1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ED50 of spinal ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MLAD of spinal ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: McGill Quality of Life (MQOL) Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Zariet Burden Interview (ZBI)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Self-reported impact of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Skin condition assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Obstructive sleep apnea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of SRT2104 as assessed by number of subjects with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of SRT2104 as assessed by change from Baseline in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of SRT2104 as assessed by change from Baseline in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-year progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: fMRI neural correlates of emotional brain processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency/severity of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Error of superimposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 months non progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acute stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in post-traumatic stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in substance abuse : alcohol
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in substance abuse : drug
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Time to reach peak or maximum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density at Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's anxiety measured by STAI/STAIC scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parents' anxiety measured by STAI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with the dentures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: disease progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: patient reported outcome pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Condition of Cold Sore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scab/Crust
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Status
Endpoint domain: Mortality/survival
Primary endpoint: Median Time for Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Pupils' diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects With at Least One Reactogenicity Sign
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Area of the StrataGraft Treatment Site Requiring Autografting by Three Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Complete Wound Closure of the Treatment Sites at Three Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NICU Network Neurobehavioral Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion Rate of oxaliplatin PEDD-PRVI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete destruction of focal tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression-free survival (PFS) in oligometastatic RCC
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (PFS) in low metastatic burden RCC
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Subjects With a Clinical Remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of the affected limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time-curve from time zero to infinity (AUC0-∞) of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time-curves from time zero to the time of last measured concentration (AUC0-last) of unconjugated ezetimibe (EZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of unconjugated ezetimibe (EZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response in Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of mortality at 28th day
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in spine bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary Albumin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Family income
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of grade 3-4 colitis
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual assault vignette measure of risk perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: off periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal postnatal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant's weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's developmental outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Exposure session attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant recruitment feasibility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Jump power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60 meters sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dose of Glucocorticoids Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fugl-Meyer Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Bronchiolitis Obliterans Syndrome (BOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rey Auditory Verbal Learning test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patients Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline average sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: development of respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hierarchical Composite Mortality
Endpoint domain: Mortality/survival
Primary endpoint: All Cause Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Absence of spontaneous pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of liver cancer
Endpoint domain: Mortality/survival
Primary endpoint: Verbal memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to Service Disengagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occurrence of myocardial infarction, stroke or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: FIT sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath analysis sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: m-YPAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Achieved a Composite 1-grade Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved a Composite 2-grade Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of Daily Living (ADL) Decline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of Subjects With a Greater Than 20% Decrease in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in total MADRS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functionality of the AVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olfactory test - Birhinal PEA threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olfactory test - UPSIT-TC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The volume of olfactory bulbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and extra pseudoanalgesia requirements change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased Radioiodine Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inpatient Psychiatric Hospitalization Rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Levels of Potassium (K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Investigator Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration in tissue biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Peak Oxygen Consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of anti-CD20 (RITUXIMAB) combined with chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroimaging Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall satisfaction with port placement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24 hour ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of extubation failure
Endpoint domain: Adverse events/effects
Primary endpoint: Number/Percentage of Subjects With Immune Response to Rotavirus Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration of Rotavirus-specific IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number and location of myocardial puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number and location of macro-bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: number of microbleeds (micro-bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: presence and location of subarachnoid hemorrhage and/or hemosiderosis
Endpoint domain: Adverse events/effects
Primary endpoint: location of the puncture infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with postoperative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes